Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode

Schizophrenia Research

Volumn 83, Issue 1, 2006, Pages 53-63

  Perkins, Diana O ^a   Johnson, Jacqueline L ^a   Hamer, Robert M ^a   Zipursky, Robert B ^b,p   Keefe, Richard S ^c   Centorrhino, Franca ^d   Green, Alan I ^d   Glick, Ira B ^e   Kahn, Rene S ^f   Sharma, Tonmoy ^g   Tohen, Mauricio ^d,h   McEvoy, Joseph P ^c,l   Weiden, Peter J ⁱ   Lieberman, Jeffrey A ^a,j   Nemeroff, Charles B ^k   Cohen, Bruce ^d   Tollefson, Gary ^h   Sanger, Todd ^h   Kuldau, John ^m   Rothschild, Anthony J ⁿ   Patel, Jayendra K ⁿ   Gur, Raquel E ^o   Daskalakis, Zafiris J ^p   Strakowski, Stephen M ^q   De Quardo, John ^r   Murray, Robin ^g   more..

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h MCLEAN HOSPITAL   (United States)

ⁱ KINGS COUNTY HOSPITAL CENTER   (United States)

^j Columbia University ^*  (United States)

^k EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l John Umstead Hospital   (United States)

^m UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

ⁿ UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^o HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^p UNIVERSITY OF TORONTO   (Canada)

^q UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^r UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

more..

Author keywords

Adherence; Compliance; First episode; HBM1; Health belief model; Schizophrenia

Indexed keywords

EID: 33645329854     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2005.10.016     Document Type: Article

References (35)

1. T.R. Barnes A rating scale for drug-induced akathisia Br. J. Psychiatry 154 1989 672 676
2. M. Byerly, R. Fisher, K. Whatley, R. Holland, F. Varghese, T. Carmody, B. Magouirk, and A.J. Rush A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia Psychiatry Res. 133 2-3 2005 129 133
3. E.L. Coldham, J. Addington, and D. Addington Medication adherence of individuals with a first episode of psychosis Acta Psychiatr. Scand. 106 4 2002 286 290
4. E. Diaz, E. Neuse, M.C. Sullivan, H.R. Pearsall, and S.W. Woods Adherence to conventional and atypical antipsychotics after hospital discharge J. Clin. Psychiatry 65 3 2004 354 360
5. C.R. Dolder, J.P. Lacro, L.B. Dunn, and D.V. Jeste Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am. J. Psychiatry 159 1 2002 103 108
6. C.R. Dolder, J.P. Lacro, S. Leckband, and D.V. Jeste Interventions to improve antipsychotic medication adherence: review of recent literature J. Clin. Psychopharmacol. 23 4 2003 389 399
7. I. Garcia-Cabeza, J.C. Gomez, J.A. Sacristan, E. Edgell, and M. Gonzalez de Chavez Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study) BMC Psychiatry 1 1 2001 7
8. M. Gitlin, K. Nuechterlein, K.L. Subotnik, J. Ventura, J. Mintz, D.L. Fogelson, G. Bartzokis, and M. Aravagiri Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia Am. J. Psychiatry 158 11 2001 1835 1842
9. I.D. Glick, and P.H. Berg Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders Int. Clin. Psychopharmacol. 17 2 2002 65 68
10. W. Guy CGI: Clinical Global Impressions. Manual for the ECDEU Assessment Battery 1970 National Institute of Mental Health Chevy Chase
11. S.R. Kay, A. Fiszbein, and L.A. Opler The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr. Bull. 13 2 1987 261 276
12. R.S. Keefe, L.J. Seidman, B.K. Christensen, R.M. Hamer, T. Sharma, M.M. Sitskoorn, R.R. Lewine, D.A. Yurgelun-Todd, R.C. Gur, M. Tohen, G.D. Tollefson, T.M. Sanger, and J.A. Lieberman Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol Am. J. Psychiatry 161 6 2004 985 995
13. M. Lambert, P. Conus, P. Eide, R. Mass, A. Karow, S. Moritz, D. Golks, and D. Naber Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence Eur. Psychiatr. 19 7 2004 415 422
14. A.F. Lehman, J.A. Lieberman, L.B. Dixon, T.H. McGlashan, A.L. Miller, D.O. Perkins, and J. Kreyenbuhl Practice guideline for the treatment of patients with schizophrenia, second edition Am. J. Psychiatry 161 Suppl. 2 2004 1 56
15. S.W. Lewis, N. Tarrier, and R.J. Drake Integrating non-drug treatments in early schizophrenia Br. J. Psychiatr., Suppl. 48 2005 s65 s71
16. J.A. Lieberman, D. Perkins, A. Belger, M. Chakos, F. Jarskog, K. Boteva, and J. Gilmore The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches Biol. Psychiatry 50 11 2001 884 897
17. J.A. Lieberman, G. Tollefson, M. Tohen, A.I. Green, R.E. Gur, R. Kahn, J. McEvoy, D. Perkins, T. Sharma, R. Zipursky, H. Wei, and R.M. Hamer Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol Am. J. Psychiatry 160 8 2003 1396 1404
18. A.K. Malla, R.M. Norman, R. Manchanda, and L. Townsend Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis Psychol. Med. 32 6 2002 1109 1119
19. J.P. McEvoy, S. Freter, G. Everett, J.L. Geller, P. Appelbaum, L.J. Apperson, and L. Roth Insight and the clinical outcome of schizophrenic patients J. Nerv. Ment. Dis. 177 1 1989 48 51
20. J. Menzin, L. Boulanger, M. Friedman, J. Mackell, and J.R. Lloyd Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program Psychiatr. Serv. 54 5 2003 719 723
21. R. Mojtabai, J. Lavelle, P.J. Gibson, N.L. Sohler, T.J. Craig, G.A. Carlson, and E.J. Bromet Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996 Psychiatr. Serv. 53 3 2002 337 339
22. S.A. Montgomery, and M. Asberg A new depression scale designed to be sensitive to change Br. J. Psychiatry 134 1979 382 389
23. S.H. Mutsatsa, E.M. Joyce, S.B. Hutton, E. Webb, H. Gibbins, S. Paul, and T.R. Barnes Clinical correlates of early medication adherence: West London first episode schizophrenia study Acta Psychiatr. Scand. 108 6 2003 439 446
24. J.L. Opolka, K.L. Rascati, C.M. Brown, and P.J. Gibson Role of ethnicity in predicting antipsychotic medication adherence Ann. Pharmacother. 37 5 2003 625 630
25. D.L. Penn, E.J. Waldheter, D.O. Perkins, K.T. Mueser, and J.A. Lieberman Psychosocial treatment for first-episode psychosis: a research update Am. J. Psychiatry 162 2005 2220 2232
26. D.O. Perkins Predictors of noncompliance in patients with schizophrenia J. Clin. Psychiatry 63 12 2002 1121 1128
27. D.O. Perkins, R.J. Wyatt, and J.J. Bartko Penny-wise and pound-foolish: the impact of measurement error on sample size requirements in clinical trials Biol. Psychiatry 47 8 2000 762 766
28. D. Robinson, M.G. Woerner, J.M. Alvir, R. Bilder, R. Goldman, S. Geisler, A. Koreen, B. Sheitman, M. Chakos, D. Mayerhoff, and J.A. Lieberman Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder Arch. Gen. Psychiatry 56 3 1999 241 247
29. D.G. Robinson, M.G. Woerner, J.M. Alvir, R.M. Bilder, G.A. Hinrichsen, and J.A. Lieberman Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder Schizophr. Res. 57 2-3 2002 209 219
30. G.M. Simpson, and J.W. Angus A rating scale for extrapyramidal side effects Acta Psychiatr. Scand., Suppl. 212 1970 11 19
31. N. Tarrier, S. Lewis, G. Haddock, R. Bentall, R. Drake, P. Kinderman, D. Kingdon, R. Siddle, J. Everitt, K. Leadley, A. Benn, K. Grazebrook, C. Haley, S. Akhtar, L. Davies, S. Palmer, and G. Dunn Cognitive-behavioural therapy in first-episode and early schizophrenia. 18-month follow-up of a randomised controlled trial Br. J. Psychiatry 184 2004 231 239
32. M. Valenstein, F.C. Blow, L.A. Copeland, J.F. McCarthy, J.E. Zeber, L. Gillon, C.R. Bingham, and T. Stavenger Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors Schizophr. Bull. 30 2 2004 255 264
33. H. Verdoux, J. Lengronne, F. Liraud, B. Gonzales, F. Assens, F. Abalan, and J. van Os Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects Acta Psychiatr. Scand. 102 3 2000 203 210
34. P. Weiden, B. Rapkin, T. Mott, A. Zygmunt, D. Goldman, M. Horvitz-Lennon, and A. Frances Rating of medication influences (ROMI) scale in schizophrenia Schizophr. Bull. 20 2 1994 297 310
35. P.J. Weiden, J.A. Mackell, and D.D. McDonnell Obesity as a risk factor for antipsychotic noncompliance Schizophr. Res. 66 1 2004 51 57